Project Grant R43DK146746
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $400K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dorchester, MA 02122, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $1,427,080 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate aberrant N-glycosylation in Crohn's disease as a pathway to precision medicine therapeutics. The research examines how defective N-glycosylation exacerbates Crohn's disease in patients carrying a pathogenic mutation in the manganese transporter ZIP8...
- The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Keybiome Inc. $1,287,812 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop AIMA, a protein-based therapeutic for inflammatory bowel disease. Keybiome is developing Aeromonas immune modulator (AIMA), an oral protein therapeutic that inhibits lipocalin 2 (LCN2), a pro-inflammatory and antimicrobial host protein elevated in IBD patients. AIMA...
- The National Institute of Child Health and Human Development awarded Duke University $593,848 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop therapeutic approaches for glutaric aciduria type I (GA-1), an autosomal recessive metabolic disorder caused by deficiency of the enzyme glutaryl-CoA dehydrogenase (GCDH). The funded research builds on prior demonstration that murine GA-1 models can be rescued through liver-directed...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beth Israel Deaconess Medical Center $164,484 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of DNAJC22 in metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research exploring DNAJC22, a gene of unknown function identified through genome-wide CRISPR-Cas9 screening and human genetic association studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $356,328 to Celdara Medical, LLC on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel allogeneic cell therapy for difficult-to-treat inflammatory bowel disease. Celdara will develop cell-based therapeutic candidates targeting the dysregulated immune response in IBD patients who fail multiple lines of conventional therapy or experience...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute of the Department of Health and Human Services National Institutes of Health, awarded $795,620 to the University of Massachusetts Medical School on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds development and validation of gene-editing technologies to engineer stem cell-derived islets for type 1 diabetes treatment. The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded United Biotherapeutics LLC $615,016 on September 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop AAV-CRISPR-engineered brown adipocytes for obesity and metabolic disorder treatment. The recipient will develop a safer and more efficient episomal AAV vector system to replace lentiviral delivery methods for generating HUMBLE cells—bioengineered brown...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Medosome Biotec LLC $356,251 on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop genetically engineered probiotics capable of producing and delivering glucagon-like peptide-1 (GLP-1) for treatment of metabolic diseases including type 2 diabetes and obesity. The project addresses limitations of existing GLP-1 receptor agonist therapies—poor patient...
- The National Heart, Lung, and Blood Institute awarded $599,669 to Kinea Bio Inc. on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate KNA-123, an innovative gene therapy for Duchenne muscular dystrophy targeting cardiac muscle degeneration. The award is classified as a Project Grant. Kinea Bio will leverage the split intein-mediated protein ligation for gene therapy (SIMPLI-GT) platform to enable delivery of a larger, more functional...